Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Antimicrobial resistance takes centre stage at ECCMID 2023, says GlobalData

Navigating the ever-increasing challenges of antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi, or parasites no longer respond to antimicrobial treatment, has been a key theme at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 conference, says GlobalData, a leading data and analytics company. Stephanie Kurdach, Infectious Disease Analyst at GlobalData, […]
Read more

FDA rejection to dent mirikizumab’s chances to become first-to-market IL-23 inhibitor therapy for ulcerative colitis in US, says GlobalData

The FDA recently rejected Eli Lilly’s biologic license application (BLA) for their anti-interleukin (IL) -23, mirikizumab, which is in development for the treatment of ulcerative colitis (UC). This news will likely delay mirikizumab’s entry into the US market as it will inevitably fall behind competitors, which are aiming to enter the UC market during 2021-31, […]
Read more

Novartis Entresto can reduce number of HF-associated hospitalizations and mortality in pediatric patients in EU if approved, says GlobalData

The goals of treatment for chronic heart failure (HF) are to relieve symptoms, prevent HF-associated hospitalizations, slow disease progression, and improve survival. The current therapies in the market are well-established. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta blockers are all used within the HF landscape regardless of type of HF. All these drugs have […]
Read more

Sanofi Soliqua will face fierce competition in price sensitive Indian T2D insulin market, says GlobalData

Sanofi (India) has recently received marketing approval by the Central Drugs Standard Control Organization (CDSCO) for soliqua (Insulin glargine and lixisenatide recombinant fixed dose combination) as an adjunct to diet and exercise in adults with obesity and type 2 diabetes (T2D), who are insufficiently controlled on oral or injectable therapies. As branded insulins become available […]
Read more
,

Arbutus patent suit against Pfizer demonstrates litigious environment in mRNA therapy, says GlobalData

Arbutus Biopharma and Genevant Sciences have recently brought a patent lawsuit against Pfizer and BioNTech in the US federal courts, surrounding the use of the lipid nanoparticle (LNP) technology used in the latter’s COVID-19 vaccines. The claim follows positive developments for the plaintiffs in their very similar lawsuit brought against Moderna last year. This latest […]
Read more

Need for improved Alzheimer’s diagnosis and management highlighted at AD/PD 2023, says GlobalData

With the advent of novel disease-modifying therapies (DMTs), the future of Alzheimer’s disease (AD) diagnosis and management has been a key theme at the AD/PD 2023 International Conference on AD and Parkinson’s disease (PD), says GlobalData, a leading data and analytics company. Pippa Salter, Senior Neurology Analyst at GlobalData, comments: “Following the FDA approvals of Biogen’s […]
Read more

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

Pharma manufacturers will be challenged by the effects of high inflation and declining FDA drug approvals in 2023. Pharmaceutical companies have a high tendency to outsource the finished dose manufacture of new molecular entities (NME). A sharp decrease in FDA approvals of the most innovative drugs in 2022 will directly reduce commercial-scale production contracts in […]
Read more

Phase IIIb results will help AbbVie Skyrizi to stand out in crowded plaque psoriasis biologics space, says GlobalData

The late-breaking data on AbbVie’s Skyrizi in plaque psoriasis (PsO) that was presented at the recently concluded American Academy of Dermatology (AAD) Annual Meeting is expected to help Skyrizi’s positioning in the crowded PsO biologics space, according to GlobalData, a leading data and analytics company. Vinie Varkey, Managing Analyst Immunology at GlobalData, comments: “The latest […]
Read more

Jyseleca safety data will allow Galapagos to build up therapy’s position in crowded UC market, says GlobalData

Following the news that Galapagos presented new efficacy and safety data of Jyseleca (filgotinib) 200mg (FIL200) therapy for the treatment of patients with ulcerative colitis (UC) being assessed in the continuing SELECTION long term extension (LTE) study: Ramla Salad, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “The encouraging SELECTION […]
Read more

HSBC acquisition of SVB UK may pave way for new opportunities in biotech sector, finds GlobalData

HSBC’s acquisition of Silicon Valley Bank UK following the collapse of its parent company Silicon Valley Bank may result in new opportunities for biopharmaceutical companies, says  GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center Deals Database, SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total […]
Read more

Regenerative medicine displays new focus on VEGF target, says GlobalData

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. Early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development, according to GlobalData, a leading data and analytics company. Regenerative medicine is an approach to […]
Read more
1 … 35 36 37 38 39 … 108